Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | CA5A | P35218 | 1/20 | 0.63 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.60 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.60 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.60 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.55 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.55 |
| ▸ | AHCY | P23526 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23474181 | 1.00 | NT5E (0.67) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL3053788 | 0.92 | NT5E (0.65) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL5362967 | 0.92 | NT5E (0.65) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL2047557 | 0.92 | NT5E (0.65) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL10684436 | 0.88 | NT5E (0.67) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL25619503 | 0.87 | DNMT1 (0.56) | ADORA2AADORA2BADORA3ADORA1DNMT1 | |
| SCHEMBL25619482 | 0.87 | DNMT1 (0.56) | ADORA2AADORA2BADORA3ADORA1DNMT1 | |
| SCHEMBL5362958 | 0.87 | NT5E (0.62) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL24220705 | 0.85 | AHCY (0.56) | NT5ELMNAHIF1ACA5AADORA2A | |
| SCHEMBL23884966 | 0.84 | ADORA3 (0.74) | NT5ELMNAHIF1ACA5AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192750-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2023-06-22 | — | — | US | disclosed |
| US-11560400-B2 | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds | NuCana plc (GB) | 2023-01-24 | — | — | US | disclosed |
| US-20220024963-A1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2022-01-27 | — | — | US | disclosed |
| US-20210171566-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NuCana plc (GB) | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171566-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NUDT1, NTPCR, TYMP | NT5E 65/4885LMNA 2971/4885HIF1A 3849/4885 |
| US-20220024963-A1 | SALT OF TRIPHOSPHATE PHOSPHORAMIDATES OF NUCLEOTIDES AS ANTICANCER COMPOUNDS | NUDT1, ITPA, MTAP | NT5E 97/4885LMNA 4331/4885HIF1A 3851/4885 |
| US-20230192750-A1 | SALTS OF DIPHOSPHATE PHOSPHORAMIDATE OF NUCLEOSIDES AS ANTICANCER COMPOUNDS | NUDT1, TYMP, NTPCR | NT5E 64/4885LMNA 3097/4885HIF1A 3846/4885 |
| US-11560400-B2 | Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds | NUDT1, NTPCR, TYMP | NT5E 65/4885LMNA 2971/4885HIF1A 3849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.